论文部分内容阅读
目的:研究布地奈德鼻喷剂联合氯雷他定在过敏性鼻炎中的临床疗效。方法:选取我院于2017年1月-2017年6月收治的84例过敏性鼻炎患者,采用随机数字法分为2组,各42例;对照组患者采用布地奈德鼻喷剂治疗,观察组则在对照组治疗基础上附加氯雷他定;治疗干预后,观察对比2组患者治疗总有效率及症状改善时间。结果:2组患者对比结果显示,观察组治疗总有效率为(92.86%/39例),对照组则为(71.43%/30例),观察组明显高于对照组,P<0.05;观察组症状改善时间为(3.01±1.03)d、对照组则为(4.56±1.45)d,观察组明显少于对照组,P<0.05,对比差异具有统计学意义。结论:在过敏性鼻炎治疗中给予布地奈德鼻喷剂联合氯雷他定具有良好临床效果,可有效缩短患者临床症状改善时间,提高临床疗效,值得用于临床推广。
Objective: To study the clinical efficacy of budesonide nasal spray combined with loratadine in allergic rhinitis. Methods: Eighty-four patients with allergic rhinitis admitted in our hospital from January 2017 to June 2017 were randomly divided into 2 groups (n = 42). The control group was treated with budesonide nasal spray In the control group, loratadine was added on the basis of the control group. After the treatment intervention, the total effective rate and symptom improvement time in the two groups were observed and compared. Results: The results of the two groups showed that the total effective rate was 92.86% / 39 in the observation group and 71.43% in the control group, the observation group was significantly higher than the control group (P <0.05); the observation group The improvement time was (3.01 ± 1.03) d in the control group and (4.56 ± 1.45) days in the control group, which was significantly lower in the observation group than in the control group (P <0.05). The difference was statistically significant. Conclusion: The budesonide nasal spray and loratadine given in the treatment of allergic rhinitis have good clinical effect, which can shorten the time of improvement of clinical symptoms and improve the clinical curative effect, which is worth to be used for clinical promotion.